Hackensack Meridian Hackensack University Medical Center Earns Joint Commission’s 29th Disease-Specific Certification


Newswise – Hackensack, NJ February 14, 2020 – Hackensack Meridian Hackensack University Medical Center has earned its 29th Joint Commission (TJC) Disease Specific Care (DSC) certification, marking the most certifications of any hospital in the nation. The last disease-specific care certification was awarded for lung cancer and demonstrates continued compliance with its performance standards. The Gold Seal is a symbol of quality that reflects a healthcare organization’s commitment to providing safe, quality patient care.

“Leading the nation with the most DSCs for a single hospital means Hackensack University Medical Center meets the highest national standards and consistently delivers superior performance while improving patient care. patients,” said Mark Sparta, FACHE, president and CEO of Hackensack University Hospital. Medical Center.

To receive the seal, Hackensack University Medical Center underwent a rigorous and unannounced examination on site. During the visit, a team of Joint Commission investigators assessed the following:

  • Compliance with related certification standards, some of which included how the lung cancer program involves patients in decision-making regarding the management of their disease.
  • Develop a care plan using an individualized interdisciplinary approach based on the patient’s assessed needs.
  • Support for patient self-management outside the hospital by involving family and community support structures in their care plan.

The Joint Commission is an independent, nonprofit organization that accredits more than twenty-two thousand healthcare organizations and programs in the United States.

“Lung cancer, including small cell and non-small cell lung cancers, is among the most complex tumors to treat,” said Lisa Tank, MD, FACP, chief medical officer at Hackensack University Medical Center. “Our top thoracic specialists carefully assess a patient’s health and personalize treatment to provide the most advanced, effective and least invasive treatments available, based on the stage and biology of the cancer. This prestigious designation is a testament to our entire care team providing patient-centered care with state-of-the-art technology and a highly tactile environment.”

“Joint Commission accreditation is a symbol of quality that reflects our organization’s commitment to raising the standard of care in New Jersey and across the country,” Sparta added. “It is an incredible achievement to be awarded this distinction and we are more than honored to be part of a team that continues to raise the bar to provide world-class care to our patients. The latest lung cancer certification is a direct result of the unparalleled expertise and dedication of our entire lung cancer team, who so deserve this distinguished recognition.


Hackensack University Medical Center, a 771-bed nonprofit teaching and research hospital, is New Jersey’s largest provider of inpatient and outpatient services. Founded in 1888 as the first hospital in Bergen County, it was the first hospital in New Jersey and the second in the nation to become a Magnet® Recognized Hospital for Nursing Excellence. The academic flagship of Hackensack Meridian Health, the Hackensack University Medical Center campus is home to facilities such as the John Theurer Cancer Center, Heart & Vascular Hospital, and Sarkis and Siran Gabrellian Women’s and Children’s Pavilion. Recognized as being in the top 1% of hospitals nationwide and #2 in New Jersey by US News and World Reports Honor Roll of “Best Hospitals” 2020-21, Hackensack University Medical Center also ranked among the top performers in Cancer Care, Cardiology and Cardiac Surgery, Gastroenterology and gastrointestinal surgery, geriatrics, nephrology, neurology and neurosurgery, orthopedics, pulmonology and urology. Hackensack University Medical Center’s comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development.


Comments are closed.